Intraocular pressure increase (IOPi) after intravitreal injections of vascular endothelial growth factor inhibitors (VEGFis) might be different between different VEGFi (bevacizumab, aflibercept, ranibizumab). The purpose of this study was to evaluate the risk of IOPi among new users of bevacizumab, ranibizumab, and aflibercept in non-diabetic patients in Tuscany, Italy.
Spini, A., Giometto, S., Donnini, S., Posarelli, M., Dotta, F., Ziche, M., et al. (2023). Risk of intraocular pressure increase with intravitreal injections of Vascular Endothelial Growth Factor Inhibitors: a cohort study. AMERICAN JOURNAL OF OPHTHALMOLOGY, 248, 45-50 [10.1016/j.ajo.2022.11.015].
Risk of intraocular pressure increase with intravitreal injections of Vascular Endothelial Growth Factor Inhibitors: a cohort study
Spini, AndreaInvestigation
;Donnini, SandraWriting – Original Draft Preparation
;Dotta, FrancescoWriting – Review & Editing
;Tosi, Gian MarcoWriting – Review & Editing
;
2023-01-01
Abstract
Intraocular pressure increase (IOPi) after intravitreal injections of vascular endothelial growth factor inhibitors (VEGFis) might be different between different VEGFi (bevacizumab, aflibercept, ranibizumab). The purpose of this study was to evaluate the risk of IOPi among new users of bevacizumab, ranibizumab, and aflibercept in non-diabetic patients in Tuscany, Italy.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0002939422004408-main.pdf
non disponibili
Tipologia:
Pre-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
550.84 kB
Formato
Adobe PDF
|
550.84 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
1-s2.0-S0002939422004408-main.pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
282.26 kB
Formato
Adobe PDF
|
282.26 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1222775